Placo (603566) Commentary on Major Issues: Proposed 100% acquisition of Nanjing Merial to enter the highly pathogenic avian influenza (H5 + H7) vaccine single product market

Placo (603566) Commentary on Major Issues: Proposed 100% acquisition of Nanjing Merial to enter the highly pathogenic avian influenza (H5 + H7) vaccine single product…